B cells, despite their several unique functionalities, remain largely untapped for use as an
adoptive cell therapy and are limited to in vitro use for antibody production. B cells can be …

A variety of bioactive materials developed to expand T cells for adoptive transfer into cancer
patients are currently evaluated in the clinic. In most cases, T cell activating biomolecules …

Artificial antigen‐presenting cells (aAPCs) are currently used to manufacture T cells for
adoptive therapy in cancer treatment, but a readily tunable and modular system can enable …

A variety of bioactive materials are currently developed to expand T cells ex vivo for adoptive
T cell immunotherapy, also known as called artificial antigen-presenting cells (aAPCs) …

Adoptive T cell therapy (ACT) has achieved remarkable results in the treatment of cancer.
Tumor‐antigen specific T cells are the main players in the clearance of cancerous cells, but …

We propose an ex vivo T cell expansion system that mimics natural antigen-presenting cells
(APCs) for adoptive cell therapy (ACT). Microfiber scaffolds coated with dendritic cell (DC) …

The development of nanocarriers capable of codelivering antigens and immune-activating
adjuvants is an emerging area of research and is relevant for cancer vaccines that target …

Protein-coated microbeads provide a consistent approach for activating and expanding
populations of T cells for immunotherapy but do not fully capture the properties of antigen …

Existing clinical cell therapies, which rely on the use of biological functionalities of living
cells, can be further enhanced by conjugating functional particles to the cells to form cell …

Microparticulate systems for delivery of therapeutics to DCs for immunotherapy have gained
attention recently. However, reports addressing the optimization of DC-targeting …